BioOncology Watch

Timely Information for Practicing Physicians

 

october 2002

 

COLON CANCER

Edrecolomab adjuvant therapy does not provide clinical benefit.  Cornelis Punt et al. conducted a large phase III trial in which 2,761 patients with resected a stage III colon cancer were randomized to receive approximately 6 months (6 cycles) of either fluorouracil-folinic acid (Mayo Clinic regimen) alone, or edrecolomab alone (administered intravenously once monthly), or combination edrecolomab plus fluorouracil-folinic acid.  After a median follow-up of 26 months (range, 20-36 months), the 3-year survival (74.7% vs. 76.1%) and disease-free survival (63.8% vs. 65.5%) rates achieved in the combination therapy and the fluorouracil-folinic acid treatment groups were similar (p=0.52 and 0.22, respectively).  In addition, the 3-year survival and disease-free survival rates of the edrecolomab-alone treatment group were less than those for patients who received fluorouracil-folinic acid alone (p=0.05 and <0.0001, respectively).  Hypersensitivity reactions occurred in 25% of patients receiving edrecolomab (4% discontinued therapy), however the addition of edrecolomab to chemotherapy did not increase the incidence of neutropenia, diarrhea, or mucositis.  This large phase III experience demonstrated that edrecolomab therapy did not enhance the clinical benefit of standard adjuvant chemotherapy for patients with Stage III colon cancer. (Punt CJA, et al. Lancet 2002;360:671-677)

 

POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE (PTLD)

Effectiveness of partly HLA-matched allogeneic cytotoxic lymphocytes (CTLs).  In a pilot study, Tanzina Haque and colleagues administered 1 to 6 infusions of partly HLA-matched allogeneic Epstein-Barr virus-specific CTLs (obtained from a frozen bank of CTLs derived from healthy blood donors) to 8 patients with PTLD unresponsive to standard treatments.  The infusions were well tolerated and neither graft-vs.-host disease nor enhanced graft rejection developed in any of the patients.  Three patients achieved a complete remission after 1-4 infusions and have remained free of disease for 11, 17, and 28 months, respectively.  One additional patient had a partial remission after 2 infusions. Two patients did not respond after 3-6 infusions and 2 patients died rapidly with progressive disease.  These preliminary results suggest that partly HLA-matched allogeneic CTLs are a potentially effective therapy against refractory PTLD and warrant further investigation.  (Haque T, et al. Lancet 2002;360:436-442)

 

RITUXIMAB

Synergy with glucocorticoids (GCs).  Although GCs are often given in conjunction with rituximab, the effects of GCs on rituximab-related antitumor mechanisms of action are unknown.  Andrea Rose and coworkers at the Fred Hutchinson Cancer Research Center (Seattle, WA) observed that the addition of dexamethasone to rituximab induced G1 arrest in all B-cell non-Hodgkin lymphoma (NHL) cell lines tested (9 of 9) and resulted in synergistic inhibition of growth in 6 of 9 cell lines.  Furthermore, combination dexamethasone and rituximab resulted in supra-additive increases of phosphatidylserine exposure and hypodiploid DNA content (in 5 and 3 cell lines, respectively). Complement-dependent and antibody-dependent cell-mediated cytotoxicities (CDC and ADCC) were not enhanced or impaired with simultaneous dexamethasone and rituximab administration.  However, pre-incubation with dexamethasone reduced cell lysis in ADCC assays in 4 cell lines, while dexamethasone pre-exposure increased cell sensitivity to CDC in 3 cell lines.  These in vitro experiments demonstrated that the addition of GCs to rituximab can result in synergistic antiproliferative and apoptotic effects in B-cell NHL cell lines and provide a rationale for clinical trials investigating the potential benefit of combination GC plus rituximab therapy.  (Rose AL, et al. Blood 2002;100:1765-1773)

 

Treatment of fludarabine-associated immune thrombocytopenia (ITP).  Upendra Hegde and colleagues from the National Cancer Institute (US) report the successful use of rituximab therapy in 3 chronic lymphocytic leukemia (CLL) patients with severe fludarabine-associated ITP (an uncommon untoward effect of fludarabine treatment).  ITP developed during the first fludarabine cycle in 1 patient and during the third cycle in 2 patients.  The platelet count nadirs were <10,000/mL in all 3 cases and did not respond to steroids or intravenous immunoglobulin administration.  Rituximab therapy (375 mg/m2 weekly for 4 weeks) resulted in an increase of the platelet counts to baseline levels in all 3 cases.  Rises in the platelet counts were noted within the first week of rituximab treatment and the response durations were 17+, 6+, and 6 months, respectively.  These results show that rituximab treatment can rapidly reverse fludarabine-associated ITP in patients with CLL.  (Hegde UP, et al. Blood 2002;100:2260-2262)

 

IMATINIB MESYLATE

Molecular targeting of platelet-derived growth factor B (PDGFB).  Imatinib mesylate (Gleevec; Novartis Pharmaceuticals) selectively inhibits PDGFB, ABL, and KIT kinases.  Brian Rubin and colleagues report the treatment of a patient with dermatofibrosarcoma protuberans, a tumor caused by the activation of the PDGFB receptor (a transmembrane tyrosine kinase), with imatinib mesylate 400 mg bid.  Within 2 weeks of treatment initiation, the hypermetabolic uptake of 18F-labeled fluorodeoxyglucose (FDG) fell to background levels by positron emission tomography.  After 4 months of therapy, tumor volume had decreased by >75% allowing for resection of the mass.  No viable tumor was found in the resected specimen (achievement of complete histologic response).  This case report demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can result in significant antineoplastic activity in at least one type of solid tumor (dermatofibrosarcoma protuberans). (Rubin BP, et al. J Clin Oncol 2002; 20:3586-3591)

 

Return to Archive

Produced by Market Development Group through an educational grant from Genentech, Inc. and IDEC Pharmaceuticals. Comments and inquiries can be e-mailed to webmaster@biooncologywatch.org